Galena Biopharma (GALE) : During the past 4 weeks, traders have been relatively bearish on Galena Biopharma (GALE), hence the stock is down -82.53% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -12.4% relative to the S&P 500. The 4-week change in the price of the stock is -81.76% and the stock has fallen -11.09% in the past 1 week. The stock has recorded a 20-day Moving Average of 67.37% and the 50-Day Moving Average is 73.12%.
Galena Biopharma (NASDAQ:GALE): The stock opened at $0.41 on Friday but the bulls could not build on the opening and the stock topped out at $0.42 for the day. The stock traded down to $0.40 during the day, due to lack of any buying support eventually closed down at $0.40 with a loss of -0.95% for the day. The stock had closed at $0.41 on the previous day. The total traded volume was 3,859,497 shares.
The company Insiders own 2.96% of Galena Biopharma shares according to the proxy statements. Institutional Investors own 13.42% of Galena Biopharma shares. In a related news, Dunlap Ryan, officer (Former Chief Financial Officer) of Galena Biopharma, Inc., unloaded 126,875 shares at an average price of $2.18 on June 1, 2016. The total amount of the transaction was worth $276,588, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug, Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.